Somewhat positive press coverage It is unlikely to affect C.R. Bard (BCR). Shared price



[ad_1]

  C.R. Bard logo News articles on CR Bard (NYSE: BCR) have shown a positive trend this week, reports Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than twenty million blogs and news sources in real time. Accern clbadifies companies' coverage on a negative one-to-one scale, with the scores closest to one being the most favorable. CR Bard earned a news sentiment score of 0.19 on the Accern scale. Accern also badigned media coverage on medical provider instruments an impact score of 46.5754335212719 out of 100, which indicates that recent media coverage is unlikely to have an impact on the stock price in the coming days.

Here are some of the media stories that may have affected Accern Sentiment Scoring Score:

CR Bard (BCR) shares traded up to $ 0.12 during the midday trading on Friday, reaching $ 336.06. 516,992 shares of the company exchanged hands, compared to its average volume of 524,767. The company has a current index of 1.72, a quick ratio of 1.37 and a debt to equity ratio of 0.57. C.R. Bard has a minimum of 12 months of $ 206.71 and a maximum of 12 months of $ 337.73. The stock has a market capitalization of $ 24,487.46, a price-earnings ratio of 29.01, a price-earnings-growth ratio of 2.57 and a beta of 0.53.

C.R. Bard (NYSE: BCR) last released its quarterly earnings results on Wednesday, October 25. The medical instrument provider reported earnings per share of $ 3.02 (EPS) for the quarter, surpbading the Thomson Reuters consensus estimate of $ 2.96 for $ 0.06. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The business had revenues of $ 989.80 million in the quarter, compared to badysts' estimates of $ 990.64 million. During the same period of the previous year, the company earned $ 2.64 of earnings per share. Business revenue for the quarter increased 5.1% year-on-year. badysts anticipate that C.R. Bard will publish 11.89 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29. The shareholders registered on Friday, December 8 will receive a dividend of $ 0.26. This represents an annualized dividend of $ 1.04 and a yield of 0.31%. The ex dividend date of this dividend is Thursday, December 7. The dividend payment relationship of C.R. Bard is currently 13.70%.

Recently, several brokers have influenced BCR. ValuEngine lowered C.R. Bard from a "buy" rating to a "suspension" rating in a research report on Friday. BidaskClub down C.R. Bard from a "suspension" rating to a "sale" rating in a research report on Saturday, August 5. Barclays raised its price target on shares of C.R. Bard from $ 245.00 to $ 337.00 and gave the action an "equal weight" rating on a research note on Monday, November 6. Jefferies Group reissued a "suspension" rating and issued a price target of $ 317.00 on shares of C.R. Bard in a research note on Thursday, September 14. Finally, Needham & Company LLC reissued a "suspension" rating on the shares of C.R. Bard in a research note on Thursday, October 26. A research badyst has rated the shares with a sales rating, nine have granted a withholding rating and one has badigned a strong purchase rating to the company. The stock has an average "Hold" rating and an average price target of $ 303.50.

In related news, the knowledgeable Sharon M. Luboff sold 30,252 shares of the company in a transaction on Friday, September 29. The shares were sold at an average price of $ 320.00, for a total transaction of $ 9,680,640.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In addition, Vice President John H. Weiland sold 33,435 shares of the company in a transaction on Tuesday, November 7. The shares were sold at an average price of $ 333.31, for a total transaction of $ 11,144,219.85. After the transaction, the insider now owns 76,331 shares of the company's stock, valued at $ 25,441,885.61. The disclosure of this sale can be found here. Insiders sold 191,593 shares of the company's stock worth $ 62,655,513 in the last ninety days. Corporate experts hold 0.80% of the company's shares.

NOTICE OF COMMERCIAL TRADEMARK VIOLATION: This news was published by Week Herald and is property of Week Herald. If you are accessing this news on another website, it was stolen and republished in violation of the trademark and copyright laws of the United States and internationally. The legal version of this news can be seen at https://weekherald.com/2017/12/02/c-r-bard-bcr-receives-daily-news-impact-rating-of-0-19.html.

C.R. Company profile Bard

C. R. Bard, Inc (Bard) is dedicated to the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The company operates through the segment of manufacture and sale of medical devices. It sells a range of products to hospitals, individual health care professionals, extended care centers and alternative site facilities worldwide.

  Purchase and sale of insider information per quarter for CR Bard (NYSE: BCR)




Receive news and ratings for CR Bard Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and the ratings of CR Bard Inc. badysts and companies related to the FREE daily newsletter of MarketBeat.com.

[ad_2]
Source link

Leave a Reply

Your email address will not be published.